• Increase font size
  • Default font size
  • Decrease font size

Schulz S, Gerhardt D, Meyer B, Seegel M, Schubach, Hopf C, Matheis K
DMSO-enhanced MALDI MS imaging with normalization against a deuterated stadard for relative quantification of dasatinib in serial mouse pharmacology studies
Anal Bioanal Chem. 2013 405(29):9467-76.

Schulz S, Göring S, Schmidt B, Hopf C
LRRK2 Kinase Inhibitors as new Drugs for Parkinson´s Disease?
In book: Emerging Drugs and Targets for Parkinson's Disease, Editors: Martinez A, Gil C,
The Royal Society of Chemistry 2013: 266-93 (chapter 11).

Fülöp A, Porada MB, Marsching C, Meyer B, Blott H, Tambe S, Sandhoff R, Junker HD, Hopf C
4-Phenyl-α-cyanocinnamic acid amide: Screening for a negative ion matrix for MALDI-MS imaging
of multiple lipid classes.
Anal Chem. 2013 85(19):9156-63.

Ruh H, Salonikios T, Fuchser J, Schwartz M, Sticht C, Hochheim C, Wirnitzer B, Gretz N, Hopf C
MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease.
J Lipid Res. 2013 54(10):2785-94.

Stettner P, Bourgeois S, Marsching C, Traykova-Brauch M, Porubsky S, Nordström V, Hopf C, Kösters R, Sandhoff R, Wiegandt H, Wagner CA, Gröne HJ, Jennemann R
Sulfatides are required for renal adaptation to chronic metabolic acidosis.
Proc Natl Acad Sci U S A 2013 110(24):9998-10003.

Ruh H, Sandhoff R, Meyer B, Gretz N, Hopf C
Quantitative Characterization of Tissue Globotetraosylceramides in a Rat Model of Polycystic Kidney Disease by PrimaDrop Sample Preparation and indirect HPTLC-MALDI-TOF MS with Automated Data Acquisition.
Anal Chem. 2013 85(13):6233-40.


Design by i-cons.ch / etosha-namibia.ch